Resources from the same session
960MO - Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC
Presenter: Daniel Catenacci
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
961MO - Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers
Presenter: Marshall Posner
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
962MO - A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Presenter: Julia Katharina Schwarze
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
963MO - Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201
Presenter: Jaume Mora
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
964MO - Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)
Presenter: Evanthia Roussos Torres
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
965MO - GTB-3550 tri-specific killer engager safely activates and delivers IL-15 to NK cells, but not T-cells, in immune suppressed patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing Her2 or B7H3
Presenter: Jeffrey Miller
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Discussion 960MO, 961MO and 962MO
Presenter: Thomas Gajewski
Session: Mini oral session - Investigational immunotherapy
Resources:
Slides
Webcast